EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Drop‐Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox–Gastaut Syndrome

Ji-Hoon Na iD, Hee Yeon Cho, Hayoon Jeon, Hyunjoo Lee, Young-Mock Lee

CNS Neuroscience & Therapeutics · 2026-11 · 32 (11)

DOI: 10.1002/cns.71221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 01.11.2026. Verfasst von Ji-Hoon Na und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Kore…. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Cannabidiol, Anticonvulsants, Seizures. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lennox–Gastaut syndrome (LGS) is a genetically heterogeneous developmental and epileptic encephalopathy in which variability in long‐term cannabidiol (CBD) response remains incompletely understood. We evaluated whether long‐term drop‐seizure response trajectories to CBD differ according to genetic status.

Methods

This single‐center retrospective longitudinal study analyzed systematically collected clinical follow‐up data from 61 patients with LGS treated with pharmaceutical‐grade CBD; 46 patients with ≥ 24 months of follow‐up were included. Patients were classified as pathogenic/likely pathogenic variant‐positive (PV+) or variant‐negative (PV–). Drop‐seizure reduction trajectories were assessed at 3‐month intervals over 24 months.

Results

Drop‐seizure reduction improved rapidly and was sustained over 24 months in both PV+ and PV– groups, with no significant differences between groups at the prespecified comparison time points. Longitudinal response trajectories showed substantial overlap, and sustained response was observed in 76.1% of patients.

Conclusion

Long‐term drop‐seizure response to CBD in LGS was sustained but not stratified by genetic status, supporting a syndrome‐level treatment approach irrespective of genetic findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lennox Gastaut SyndromeCannabidiolAnticonvulsantsSeizuresHumansLongitudinal StudiesFemaleRetrospective StudiesMaleChildChild, PreschoolAdolescentTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Lennox–Gastaut syndromecannabidioldrop seizureslong‐term follow‐uptreatment responsewhole‐exome sequencing

Substanzen

CannabidiolAnticonvulsants

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Ji-Hoon Na

Zitieren

APA

Na, J. H., Cho, H. Y., Jeon, H., Lee, H., & Lee, Y. M. (2026). Long‐Term Drop‐Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox–Gastaut Syndrome. CNS Neuroscience & Therapeutics, 32(11). https://doi.org/10.1002/cns.71221

Vancouver

Na JH, Cho HY, Jeon H, Lee H, Lee YM. Long‐Term Drop‐Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox–Gastaut Syndrome. CNS Neuroscience & Therapeutics. 2026;32(11). doi:10.1002/cns.71221

BibTeX
@article{Na2026,
  author = {Na, Ji-Hoon and Cho, Hee Yeon and Jeon, Hayoon and Lee, Hyunjoo and Lee, Young-Mock},
  title = {Long‐Term Drop‐Seizure Response Patterns to Cannabidiol According to Genetic Status in Lennox–Gastaut Syndrome},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {11},
  doi = {10.1002/cns.71221}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche